Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019

Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network assessed interim 2018/19 vaccine effectiveness (VE) against predominant influenza A(H1N1)pdm09 viruses. Adjusted VE was 72% (95% confidence interval: 60 to 81) against medically attended, laboratory-confirmed influ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Euro surveillance : bulletin européen sur les maladies transmissibles 2019-01, Vol.24 (4), p.1
Hauptverfasser: Skowronski, Danuta M, Leir, Siobhan, Sabaiduc, Suzana, Murti, Michelle, Dickinson, James A, Olsha, Romy, Gubbay, Jonathan B, Croxen, Matthew A, Charest, Hugues, Chan, Tracy, Bastien, Nathalie, Li, Yan, Krajden, Mel, De Serres, Gaston
Format: Artikel
Sprache:eng
Schlagworte:
Children & youth
Confidence intervals
COVID-19 vaccines
Influenza
Rapid Communication
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network assessed interim 2018/19 vaccine effectiveness (VE) against predominant influenza A(H1N1)pdm09 viruses. Adjusted VE was 72% (95% confidence interval: 60 to 81) against medically attended, laboratory-confirmed influenza A(H1N1)pdm09 illness. This substantial vaccine protection was observed in all age groups, notably young children who appeared to be disproportionately affected. Sequence analysis identified heterogeneity in emerging clade 6B.1 viruses but no dominant drift variant.
ISSN:1560-7917
1025-496X
1560-7917
DOI:10.2807/1560-7917.ES.2019.24.4.1900055